News

 RB CEO Rakesh Kapoor said: “The acquisition of Mead Johnson is a significant step forward in RB’s journey as a leader in consumer health. With the Enfa family

The study was conducted by the Clinical Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). In the trial, TRC105 combined with Avastin (bevacizumab) was compared to

Cinven has proposed to buy all the shares of Stada in a takeover offer, with each of them priced at €56. The offer from the other unnamed bidder has

Under an exclusive global licensing agreement, Seattle Genetics will develop, fund, manufacture and commercialize Immunomedics’ solid tumor therapy candidate, IMMU-132. Seattle will also take the responsibility to start

The stay order passed by the US Court of Appeals for the Federal Circuit will allow both the firms to appeal against the ruling of a federal judge in a

The clinical study will be conducted across approximately 15 centers in the United States. Jazz Pharmaceuticals research and development global head and development and chief medical officer Karen

GSD Ia is a rare, orphan genetic disease that results in excess accumulation of glycogen and lipids in liver tissue.  Data to date showed that treatment with VK2809

With unique MistPro technology, Flonase Sensimist delivers a fine, gentle, yet powerful mist spray, providing non-drowsy, 24-hour relief of allergy symptoms including itchy, watery eyes, nasal congestion, runny

Emflaza is a corticosteroid that works by decreasing inflammation and reducing the activity of the immune system. The drug’s effectiveness was demonstrated in a clinical study of 196